Development of an intranasal, universal influenza vaccine in an EU-funded public-private partnership: the FLUniversal consortium
Influenza is a significant global health problem, causing disease and hospitalisations in elderly individuals and infants. While updated vaccines are available every year, their effectiveness is moderate at best. FLUniversal is a European Union funded consortium, aiming to develop a universal influe...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1568778/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849309495962894336 |
|---|---|
| author | Victor M. Cnossen Paula C. Leao Moreira Othmar G. Engelhardt Jerzy Samolej Geert H. Groeneveld Geert H. Groeneveld Simon P. Jochems Wesley Huisman Gabriel K. Pedersen Katharina Wørzner Lukas Recek Giulia Piccini Claudia M. Trombetta Claudia M. Trombetta Amy Aspelund Alaura Hoag Manfred Reiter Carrie Wick Thomas Muster Ingrid Maria Catharina Kamerling Ingrid Maria Catharina Kamerling |
| author_facet | Victor M. Cnossen Paula C. Leao Moreira Othmar G. Engelhardt Jerzy Samolej Geert H. Groeneveld Geert H. Groeneveld Simon P. Jochems Wesley Huisman Gabriel K. Pedersen Katharina Wørzner Lukas Recek Giulia Piccini Claudia M. Trombetta Claudia M. Trombetta Amy Aspelund Alaura Hoag Manfred Reiter Carrie Wick Thomas Muster Ingrid Maria Catharina Kamerling Ingrid Maria Catharina Kamerling |
| author_sort | Victor M. Cnossen |
| collection | DOAJ |
| description | Influenza is a significant global health problem, causing disease and hospitalisations in elderly individuals and infants. While updated vaccines are available every year, their effectiveness is moderate at best. FLUniversal is a European Union funded consortium, aiming to develop a universal influenza vaccine by bringing together partners with expertise in different areas of vaccine development. An intranasal live attenuated vaccine, DeltaFLU, will be produced using an innovative platform; preclinical assessment in animal models and clinical studies using a controlled human infection model (CHIM) will be conducted for assessment of safety, immunogenicity and protective efficacy; and finally, comprehensive immunological analysis of blood and nasal mucosa will elucidate vaccine responses and potential new correlates of protection (CoPs). In addition to a universal influenza vaccine, listed as a top priority by the EU, FLUniversal seeks to deliver an enhanced vaccine manufacturing technology that is superior in terms of efficiency, production costs and production speed - especially critical in the face of a potential new pandemic. Moreover, an influenza CHIM with a focus on harmonisation of clinical procedures and assays will be established to generate translatable and reproducible data. Newly generated knowledge on mechanisms of protection, CoPs and new molecular analysis tools may significantly contribute to our knowledge on influenza infection and influenza vaccines. In conclusion, FLUniversal is an innovative and ambitious public-private partnership, aiming to present a new development pathway for influenza vaccines, and maximising impact by bringing together leading partners from academy and industry with a shared purpose of collaboration and innovation. |
| format | Article |
| id | doaj-art-fbddb0ccf1254afbb73656a732e4162f |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-fbddb0ccf1254afbb73656a732e4162f2025-08-20T03:54:07ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-05-011610.3389/fimmu.2025.15687781568778Development of an intranasal, universal influenza vaccine in an EU-funded public-private partnership: the FLUniversal consortiumVictor M. Cnossen0Paula C. Leao Moreira1Othmar G. Engelhardt2Jerzy Samolej3Geert H. Groeneveld4Geert H. Groeneveld5Simon P. Jochems6Wesley Huisman7Gabriel K. Pedersen8Katharina Wørzner9Lukas Recek10Giulia Piccini11Claudia M. Trombetta12Claudia M. Trombetta13Amy Aspelund14Alaura Hoag15Manfred Reiter16Carrie Wick17Thomas Muster18Ingrid Maria Catharina Kamerling19Ingrid Maria Catharina Kamerling20Centre for Human Drug Research, Leiden, NetherlandsCentre for Human Drug Research, Leiden, NetherlandsMedicines and Healthcare Products Regulatory Agency, Potters Bar, United KingdomMedicines and Healthcare Products Regulatory Agency, Potters Bar, United KingdomLeiden University Center for Infectious Diseases (LU-CID), Leiden University Medical Center, Leiden, NetherlandsDepartment of Internal Medicine - Acute Internal Medicine, Leiden University Medical Center, Leiden, NetherlandsLeiden University Center for Infectious Diseases (LU-CID), Leiden University Medical Center, Leiden, NetherlandsLeiden University Center for Infectious Diseases (LU-CID), Leiden University Medical Center, Leiden, NetherlandsCenter for Vaccine Research, Statens Serum Institut, Copenhagen, DenmarkCenter for Vaccine Research, Statens Serum Institut, Copenhagen, DenmarkMediTox S.R.O., Konárovice, CzechiaVisMederi S.r.l., Siena, ItalyVisMederi S.r.l., Siena, ItalyDepartment of Molecular and Developmental Medicine, University of Siena, Siena, ItalyVivaldi Biosciences, Vienna, AustriaVivaldi Biosciences, Vienna, AustriaVivaldi Biosciences, Vienna, AustriaVivaldi Biosciences, Vienna, AustriaVivaldi Biosciences, Vienna, AustriaCentre for Human Drug Research, Leiden, NetherlandsLeiden University Center for Infectious Diseases (LU-CID), Leiden University Medical Center, Leiden, NetherlandsInfluenza is a significant global health problem, causing disease and hospitalisations in elderly individuals and infants. While updated vaccines are available every year, their effectiveness is moderate at best. FLUniversal is a European Union funded consortium, aiming to develop a universal influenza vaccine by bringing together partners with expertise in different areas of vaccine development. An intranasal live attenuated vaccine, DeltaFLU, will be produced using an innovative platform; preclinical assessment in animal models and clinical studies using a controlled human infection model (CHIM) will be conducted for assessment of safety, immunogenicity and protective efficacy; and finally, comprehensive immunological analysis of blood and nasal mucosa will elucidate vaccine responses and potential new correlates of protection (CoPs). In addition to a universal influenza vaccine, listed as a top priority by the EU, FLUniversal seeks to deliver an enhanced vaccine manufacturing technology that is superior in terms of efficiency, production costs and production speed - especially critical in the face of a potential new pandemic. Moreover, an influenza CHIM with a focus on harmonisation of clinical procedures and assays will be established to generate translatable and reproducible data. Newly generated knowledge on mechanisms of protection, CoPs and new molecular analysis tools may significantly contribute to our knowledge on influenza infection and influenza vaccines. In conclusion, FLUniversal is an innovative and ambitious public-private partnership, aiming to present a new development pathway for influenza vaccines, and maximising impact by bringing together leading partners from academy and industry with a shared purpose of collaboration and innovation.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1568778/fullinfluenzavaccineuniversal influenza vaccineFLUniversalcontrolled human infection modelpublic-private partnerships |
| spellingShingle | Victor M. Cnossen Paula C. Leao Moreira Othmar G. Engelhardt Jerzy Samolej Geert H. Groeneveld Geert H. Groeneveld Simon P. Jochems Wesley Huisman Gabriel K. Pedersen Katharina Wørzner Lukas Recek Giulia Piccini Claudia M. Trombetta Claudia M. Trombetta Amy Aspelund Alaura Hoag Manfred Reiter Carrie Wick Thomas Muster Ingrid Maria Catharina Kamerling Ingrid Maria Catharina Kamerling Development of an intranasal, universal influenza vaccine in an EU-funded public-private partnership: the FLUniversal consortium Frontiers in Immunology influenza vaccine universal influenza vaccine FLUniversal controlled human infection model public-private partnerships |
| title | Development of an intranasal, universal influenza vaccine in an EU-funded public-private partnership: the FLUniversal consortium |
| title_full | Development of an intranasal, universal influenza vaccine in an EU-funded public-private partnership: the FLUniversal consortium |
| title_fullStr | Development of an intranasal, universal influenza vaccine in an EU-funded public-private partnership: the FLUniversal consortium |
| title_full_unstemmed | Development of an intranasal, universal influenza vaccine in an EU-funded public-private partnership: the FLUniversal consortium |
| title_short | Development of an intranasal, universal influenza vaccine in an EU-funded public-private partnership: the FLUniversal consortium |
| title_sort | development of an intranasal universal influenza vaccine in an eu funded public private partnership the fluniversal consortium |
| topic | influenza vaccine universal influenza vaccine FLUniversal controlled human infection model public-private partnerships |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1568778/full |
| work_keys_str_mv | AT victormcnossen developmentofanintranasaluniversalinfluenzavaccineinaneufundedpublicprivatepartnershipthefluniversalconsortium AT paulacleaomoreira developmentofanintranasaluniversalinfluenzavaccineinaneufundedpublicprivatepartnershipthefluniversalconsortium AT othmargengelhardt developmentofanintranasaluniversalinfluenzavaccineinaneufundedpublicprivatepartnershipthefluniversalconsortium AT jerzysamolej developmentofanintranasaluniversalinfluenzavaccineinaneufundedpublicprivatepartnershipthefluniversalconsortium AT geerthgroeneveld developmentofanintranasaluniversalinfluenzavaccineinaneufundedpublicprivatepartnershipthefluniversalconsortium AT geerthgroeneveld developmentofanintranasaluniversalinfluenzavaccineinaneufundedpublicprivatepartnershipthefluniversalconsortium AT simonpjochems developmentofanintranasaluniversalinfluenzavaccineinaneufundedpublicprivatepartnershipthefluniversalconsortium AT wesleyhuisman developmentofanintranasaluniversalinfluenzavaccineinaneufundedpublicprivatepartnershipthefluniversalconsortium AT gabrielkpedersen developmentofanintranasaluniversalinfluenzavaccineinaneufundedpublicprivatepartnershipthefluniversalconsortium AT katharinawørzner developmentofanintranasaluniversalinfluenzavaccineinaneufundedpublicprivatepartnershipthefluniversalconsortium AT lukasrecek developmentofanintranasaluniversalinfluenzavaccineinaneufundedpublicprivatepartnershipthefluniversalconsortium AT giuliapiccini developmentofanintranasaluniversalinfluenzavaccineinaneufundedpublicprivatepartnershipthefluniversalconsortium AT claudiamtrombetta developmentofanintranasaluniversalinfluenzavaccineinaneufundedpublicprivatepartnershipthefluniversalconsortium AT claudiamtrombetta developmentofanintranasaluniversalinfluenzavaccineinaneufundedpublicprivatepartnershipthefluniversalconsortium AT amyaspelund developmentofanintranasaluniversalinfluenzavaccineinaneufundedpublicprivatepartnershipthefluniversalconsortium AT alaurahoag developmentofanintranasaluniversalinfluenzavaccineinaneufundedpublicprivatepartnershipthefluniversalconsortium AT manfredreiter developmentofanintranasaluniversalinfluenzavaccineinaneufundedpublicprivatepartnershipthefluniversalconsortium AT carriewick developmentofanintranasaluniversalinfluenzavaccineinaneufundedpublicprivatepartnershipthefluniversalconsortium AT thomasmuster developmentofanintranasaluniversalinfluenzavaccineinaneufundedpublicprivatepartnershipthefluniversalconsortium AT ingridmariacatharinakamerling developmentofanintranasaluniversalinfluenzavaccineinaneufundedpublicprivatepartnershipthefluniversalconsortium AT ingridmariacatharinakamerling developmentofanintranasaluniversalinfluenzavaccineinaneufundedpublicprivatepartnershipthefluniversalconsortium |